Skip to main content

Table 2 Reproductive endocrine parameters in women with prior menstrual disorders and controls before and after HRT

From: Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders

Variable Perimenopausal Postmenopausal
Normal menstruation
(N = 410)
Menstrual disorders
(N = 46)
P valuea Normal menstruation
(N = 120)
Menstrual disorders
(N = 19)
P valuea
E2 (pmol/L)
 Before HRT 63 (28.46, 139.18) 43.52 (18.35, 110.13) 0.11 43.31 (18.35, 76.81) 38.24 (18.40, 57.49) 0.45
 After HRT 195.95 (121.43, 309.67) 205.50 (129.50,440.70) 0.24 166.60 (90.67, 248.89) 98.92 (45.80, 153.00) 0.05
P valueb 0.000 0.000   0.000 0.02  
 Δ E2 (pmol/L) 118.89 (11.23, 228.34) 164.63 (38.43, 361.75) 0.12 89.13 (27.49, 176.74) 55.61 (0.00, 112.65) 0.19
FSH (IU/L)
 Before HRT 69.50 (51.81, 89.60) 69.30 (55.22, 98.60) 0.37 76.73 ± 28.85 74.22 ± 35.02 0.73
 After HRT 43.00 (27.68, 62.46) 43.64 (23.87, 58.39) 0.82 53.86 ± 27.01 54.93 ± 25.76 0.87
P valueb 0.000 0.000   0.000 0.005  
 Δ FSH (IU/L) −23.51(−43.71, −5.51) −28.00(−45.20, −16.01) 0.19 −22.87 ± 25.45 −19.30 ± 25.95 0.57
LH (IU/L)
 Before HRT 37.74 (28.80, 48.57) 39.17 (29.32, 50.67) 0.54 35.19 (27.99, 45.96) 35.03 (24.38, 43.38) 0.76
 After HRT 29.04 (18.48, 39.66) 30.27 (18.74, 41.85) 0.55 30.59 (20.89, 39.74) 31.90 (17.73, 40.77) 0.94
P valueb 0.000 0.001   0.000 0.09  
 Δ LH (IU/L) −9.09 ± 17.11 −8.61 ± 17.05 0.86 −6.86(−12.85, 2.81) −2.61(−9.73, 4.50) 0.46
  1. Data are expressed as medians (25th percentile, 75th percentiles) or mean ± standard deviation as appropriate. P < 0.05 was considered significant.Value of the difference between the baseline and follow-up reproductive endocrine parameters (E2, FSH, and LH). aP values are for between-group differences by Mann-Whitney U test or independent samples t-test. bP values are for within-group differences by Wilcoxon signed-rank test or paired-samples t test
  2. Others: E2 estradiol, FSH follicle-stimulating hormone, HRT hormone replacement therapy, LH luteinizing hormone